Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceramide nanoliposomal - PendreaBio

Next Previous
Drug Profile

Ceramide nanoliposomal - PendreaBio

Alternative Names: Ceramide NanoLiposome; Ceraxa; CNL; KN 001; KN-001 - PendreaBio; KN-01; Nanoliposomal ceramide

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Keystone Nano
  • Developer PendreaBio; University of Virginia
  • Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
  • Mechanism of Action Undecaprenyl pyrophosphate synthetase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Prostate cancer
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Liposomal)
  • 21 Jan 2021 Keystone Nano plans a phase I trial for Acute Myeloid Leukemia (Second-line therapy or greater) in USA in February 2021 (NCT04716452; KNAN2001 )
  • 22 Jun 2020 Pharmacodynamics data from a preclinical study in Prostate cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top